SELLAS Among Top Performing Stocks in June 2026 Amid Phase 3 Trial Progress

SELLAS Life Sciences Group (SLS) is highlighted as one of the top-performing American stocks for June 2026 due to progress in its Galinpepimut-S Phase 3 trial and a raised price target by Alliance Global. The firm's analyst James Molloy increased his price target from $10 to $25, maintaining a 'Buy' rating.

By Jeff Lewis Thu, July 9, 2026 at 1:38 PM GMT+3 2 min read · Yahoo Finance · July 9, 2026, 10:38 UTC

SELLAS Among Top Performing Stocks in June 2026 Amid Phase 3 Trial Progress

Topics: analyst upgrade phase 3 clinical trials stock performance

Read the full article at Yahoo Finance

More World news

Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC